Serstech
Michael Sandin Appointed Interim CFO of Serstech
Michael Sandin Appointed Interim CFO of Serstech
Serstech’s Chief Financial Officer, Simon Persson, will be on parental leave from June 1 to October 31, 2025. During this period, Michael Sandin will assume the role of interim CFO.
Michael Sandin brings over 30 years of experience in finance, including roles as an accountant and as CEO of Outbrave Finance, based in Malmö. Michael has a degree in finance from Lund University in Sweden.
“We are pleased to welcome Michael to the Serstech team during Simon’s temporary leave. His extensive experience will ensure continued financial leadership and stability during this period,” says Stefan Sandor, CEO of Serstech.
For further information, please contact:
Stefan Sandor,
CEO, Serstech AB
Phone: +46 739 606 067
Email: ss@serstech.com
or
Thomas Pileby,
Chairman of the Board, Serstech AB
Phone: +46 702 072 643
Email: tp@serstech.com
or visit: www.serstech.com
Certified advisor to Serstech is Svensk Kapitalmarknadsgranskning AB (SKMG).
About Serstech
Serstech delivers solutions for chemical identification and has customers around the world, mainly in the safety and security industry. Typical customers are customs, police authorities, security organizations and first responders. The solutions and technology are however not limited to security applications and potentially any industry using chemicals of some kind could be addressed by Serstech’s solution. Serstech’s head office is in Sweden and all production is done in Sweden.
Serstech is traded at Nasdaq First North Growth Market and more information about the company can be found at www.serstech.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
SkiStar AB13.12.2025 16:00:00 CET | Press release
Bulletin from Annual General Meeting of SkiStar AB
Robex Resources Inc.13.12.2025 06:31:43 CET | Press release
Robex Files Addendum to Information Circular in Connection With Amendment to Arrangement Agreement With Predictive Discovery
Teva Pharmaceutical Industries Ltd12.12.2025 22:30:00 CET | Press release
Teva Releases Q4 2025 Aide Memoire
Teva Pharmaceutical Industries Ltd12.12.2025 22:30:00 CET | Press release
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
Ingredion Incorporated12.12.2025 22:06:36 CET | Press release
Ingredion Incorporated Declares Quarterly Dividend of $0.82 Per Share
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom